Article Tools
Add to My Bookmarks
Adds Article to your Entrepreneur Assist Bookmark page.
CHAPEL HILL -- Pozen expects to hear by mid-April whether its
migraine treatment will be approved by the federal Food and Drug
Administration. In August, the agency requested further study of whether
Treximet, formerly known as Trexima, could cause genetic damage. Pozen
submitted the latest study to the FDA in March. Treximet would be its
first product.
COPYRIGHT 2008 Business North
Carolina Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
Copyright 2008 Gale, Cengage Learning. All rights
reserved. Gale Group is a Thomson Corporation Company.
NOTE: All illustrations and photos have been removed from this article.
Browse by Journal Name: